Status:
Ready to upload
Record number:
1763
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
N/A. Literature review of various tumor types: systematic review of donor cancer transmission to kidney recipients up to December 2012 (69 studies included with 104 recipients): renal cancer (n=20), melanoma (n=18), lymphoma (n=15), lung cancer (n=9), sarcoma (n=7), Glioma (n=6), Choricarcinoma (n=5); other cancers (n=24).
Please note that the cases have already been published in other studies and are summarized in this review for the outcome parameters: cancer specfic recipient survival, frequencies of metastasis at initial cancer diagnosis, time to cancer diagnosis, treatment modalities.
Time to detection:
Time from transplantation to cancer detection in months: median-IQR: renal cancer (n=20: 10.5; 3.0-40.0), melanoma (n=18: 10.5; 8.0-16.5), lymphoma (n=15; 4.0; 0.8-7.0), lung cancer (n=9: 13.0; 11.0-17.0), sarcoma (n=7: 19.0; 14.3-20.0), glioma (n=6: 10.0; 10.0-17.0), choricarcinoma (n=5: 1.0; 0.2-3.0); other cancers (n=24: 8.0; 5.5-18.5). Except for glioma all other cancers were not known to implanting team at time of transplantation.
Alerting signals, symptoms, evidence of occurrence:
Except for time to detection alerting signals and symptoms must be extracted from the original references.
At time of diagnosis recipients with metastases were observed in renal cancer in 15% (n=3) cases, in melanoma in 72% (n=13) cases, in lymphoma in 7% (n=1) cases, in lung cancer in 78% (n=7) cases, in sarcoma in 71% (n=5) cases, in glioma in 17% (n=1) cases, in choricarcinoma in 40% (n=2) cases, other cancers in 71% (n=17) cases.
Time interval from transplantation to recipient death (number of events; time in months: median; IQR) in renal cancer 3 of 17: 9.0: 6.7-9.5; in melanoma 13 of 18: 12.5; 10.1-17.8; in lung cancer 6 of 9: 25.0; 18.0-37.0; in lymphoma 1 of 15: 1. 1-1.
Demonstration of imputability or root cause:
N/A. Details must be extracted from original references.
Imputability grade:
Not Assessable
Groups audience:
Keywords:
Suggest new keywords:
Subject review
Living donor
Deceased donor
Kidney transplant
Lymphoma/type not specified
Astrocytoma/glioblastoma multiforme (WHO grade 4)
Renal cell carcinoma
Sarcoma/other or type not specified
Melanoma
Choriocarcinoma
Lung cancer/adenocarcinoma
Malignancy
Reference attachment:
Suggest references:
Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: A systematic review. Am J Transplant 2013; 13:2645-2652.
Note:
This paper can be used as the basis for several records, dealing with RCC (this one), lung cancer and melanoma, and maybe others. The paper is restricted to kidney recipient.
Please check: harm to reciepient should include a mark at renal cell cancer, lymphoma, melanoma, choriocarcinoma, lung cancer, sarcoma.
This record can be cloned for lymphoma, melanoma, choriocarcinoma, lung cancer, sarcoma Mike N.
This record will be cloned for the 5 requested tumor types (EP)
Expert comments for publication:
The authors conclude with the general consensus that organs from donors with a history of melanoma or lung cancer should be rejected for transplantation but state that their review suggests that use of donor kidneys with a history of small incidental renal cell cancers may be reasonable.